P3 Health Partners: When $45M of Settlements Hides a $9M Core

Favorable payer settlements flipped from headwind to tailwind, lifting Q2 EBITDA to $54M — but the 'underlying' business still has to prove it can stand alone.

PIII · Earnings Call · 2026-08-10

From Headwind to Tailwind: The Settlement Flip

P3 Health Partners — the ~133,000-life Medicare Advantage and managed-services platform — just posted its strongest single quarter in years, and the tape is already voting: +306% over the last 90 trading days against a full-history drawdown of 98%. Q2 2026 adjusted EBITDA came in at $54M versus a -$17M loss a year earlier, and first-half adjusted EBITDA reached $80M against -$39M in H1 2025. Full-year guidance was raised to $80–110M with a $95M midpoint, and operating income swung to +$8M — the first positive print in the quarterly series.

But the honest read of the bridge is where it gets interesting. Nearly all of the gain came from the line that has been P3's recurring source of volatility: favorable payer settlements. CFO Leif Pedersen was unusually explicit about slicing it:

Q2 adjusted EBITDA was $54.4 million less $45 million of favorable prior period development and payer settlement... the payer settlement amount was $41 million. And that did not affect revenue. That only affected medical claims expense.
Leif Pedersen, CFO · 2026-08-10

So the reported number is roughly five times the underlying result — about $9M of core EBITDA on $386M of revenue. A year ago, the same line was cutting the other way: in Q2 2025 the company absorbed “a net $9 million of out of period that impacted Q2 unfavorably” — Leif Pedersen, Executive (likely CFO) · 2025-08-14, and in Q3 2025 a “$21 million impact” — Leif Pedersen, Chief Financial Officer · 2025-11-14 from a midyear true-up. The swing from penalties to settlements is itself the evidence that 18 months of contract restructuring worked — but it also frames the durability question.

The Durability Argument: Medical Trend and Point-of-Care

Why the market is paying up anyway is the operational proof. Management's headline claim is that MA medical cost trend ran 1.8% below the FY2025 baseline in the first half, in a sector where the CEO says peers are running 5% to 7% higher year over year (“This is a significant and sustained differentiator in the sector when compared to peers running 5% to 7% year over year” — Aric Coffman, CEO · 2026-08-10). The engine behind that is the point-of-care tooling now reaching over 65,000 lives — roughly 110% of the original year-end goal — with providers closing nearly 90% of care gaps during visits, plus the payment integrity and utilization management programs tracking at or above plan. Quality is ahead of the internal glide path toward 4-star HEDIS and medication-adherence measures, and alternative quality submissions tripled year over year.

The CFO frames it as a structural milestone: “Importantly, the underlying business is profitable and improved quarter over quarter.” — Leif Pedersen, CFO · 2026-08-10 The Nebraska expansion — a services-only relationship until full risk begins in 2028 — adds a deliberate, low-downside growth leg (“we do not move into the full risk arrangement until 2028” — Aric Coffman, CEO · 2026-08-10).

The Contrarian Read: What's Recurring vs. Episodic?

Do the math on the guidance and the earnings-quality tension is stark. The $95M midpoint decomposes into roughly $33M of underlying EBITDA — $18M in H1 plus about $15M more in H2, per the CFO's own split — and ~$62M of settlement and prior-year-development items that are, by definition, not recurring. That means well over half the year's guided profit is one-time in nature. When Ryan Langston asked how the back half shapes up, Pedersen answered directly: “from an underlying EBITDA perspective, that would be about $15 million of additional EBITDA in the back half of the year.” — Leif Pedersen, CFO · 2026-08-10

There's also the balance sheet. At-risk membership is down ~10% year over year to ~105,000 by deliberate design, and the PMPM funding improvement of ~15% is doing the revenue lifting — Q2 revenue of $386M is up 4% YoY on a smaller book. Meanwhile effective net cash sits at -$353M — a levered turnaround that has already been bid up about four-fold in three months. The favorable-payer-settlement keyword spiking to the top of P3's own keyword ranks this quarter — after four straight quarters of negative prior-period items — is exactly the kind of reversal the market loves to front-run. Whether the medical cost trend proof holds through the back-half seasonal build is the real test of whether this is durability or a one-time repricing.